Sinovac Biotech (FRA:SVQ) Marketable Securities: €4,514.4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SVQ Sinovac Biotech Ltd FRA:SVQ
12 GF Score
Price €5.58
! 9 Warning Signs
View Full Analysis

What is Sinovac Biotech Marketable Securities?

Sinovac Biotech FRA:SVQ 12 Marketable Securities is €4,514.4 Mil as of Jun. 2026. GuruFocus rates FRA:SVQ with a GF Score™ of 12/100. The stock has 9 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sinovac Biotech's Marketable Securities for the quarter that ended in Jun. 2026 was €4,514.4 Mil.

Sinovac Biotech's annual Marketable Securities increased from Dec. 2023 (€9,126.9 Mil) to Dec. 2024 (€9,180.7 Mil) but then declined from Dec. 2024 (€9,180.7 Mil) to Dec. 2025 (€4,682.5 Mil).

Sinovac Biotech  (FRA:SVQ) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sinovac Biotech Marketable Securities Related Terms

Sinovac Biotech Marketable Securities Historical Data

* Premium members only.

The historical data trend for Sinovac Biotech's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinovac Biotech Marketable Securities Chart

Sinovac Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,598.71 6,640.63 9,126.94 9,180.73 4,682.54

Sinovac Biotech Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,827.53 9,180.73 5,009.31 4,682.54 4,514.43
FRA:SVQ
12GF Score
Sinovac Biotech Ltd FRA:SVQ
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinovac Biotech Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €4,514.4 Mil mean?
Sinovac Biotech (FRA:SVQ) has a Marketable Securities of €4,514.4 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sinovac Biotech and its competitors.
Is Sinovac Biotech's Marketable Securities too high?
Sinovac Biotech's current Marketable Securities is €4,514.4 Mil. Overall, Sinovac Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sinovac Biotech's Marketable Securities compare to INBX and HLVX?
Sinovac Biotech's Marketable Securities of €4,514.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sinovac Biotech and its competitors. Sinovac Biotech's current Marketable Securities is €4,514.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinovac Biotech stock overvalued right now?
Sinovac Biotech (FRA:SVQ) has a current Marketable Securities of €4,514.4 Mil. The current Marketable Securities is €4,514.4 Mil. Sinovac Biotech's overall GF Score™ is 12/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Sinovac Biotech (FRA:SVQ), the current Marketable Securities is €4,514.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sinovac Biotech Business Description

Address No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
12GF Score

Get the complete analysis for FRA:SVQ

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.58
Price